PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties
- PMID:21982571
- DOI: 10.1016/j.nucmedbio.2011.02.014
PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties
Abstract
Introduction: Radiolabeled bombesin (BN) conjugates are promising radiotracers for imaging and therapy of breast and prostate tumors in which BN(2)/gastrin-releasing peptide (GRP) receptors are overexpressed. However, the low in vivo stability of BN conjugates may limit their clinical application. In an attempt to improve their pharmacokinetics and counteract their rapid enzymatic degradation, we prepared a series of polyethylene glycol (PEG)-ylated BN(7-14) analogues for radiolabeling with (99m)Tc(CO)(3) and evaluated them in vitro and in vivo.
Methods: Derivatization of a stabilized (N(α)His)Ac-BN(7-14)[Cha(13),Nle(14)] analogue with linear PEG molecules of various sizes [5 kDa (PEG(5)), 10 kDa (PEG(10)) and 20 kDa (PEG(20))] was performed by PEGylation of the ɛ-amino group of a β(3)hLys-βAla-βAla spacer between the stabilized BN sequence and the (N(α)His)Ac chelator. The analogues were then radiolabeled by employing the (99m)Tc-tricarbonyl technique. Binding affinity and internalization/externalization studies were performed in vitro in human prostate carcinoma PC-3 cells. Stability was investigated in vitro in human plasma and in vivo in Balb/c mice. Finally, single photon emission computed tomography (SPECT)/X-ray computed tomography studies were performed in nude mice bearing PC-3 tumor xenografts.
Results: PEGylation did not affect the binding affinity of BN analogues, as the binding affinity for BN(2)/GRP receptors remained high (K(d)<0.9 nM). However, in vitro binding kinetics of the PEGylated analogues were slower. Steady-state condition was reached after 4 h, and the total cell binding was 10 times lower than that for the non-PEGylated counterpart. Besides, PEGylation improved the stability of BN conjugates in vitro and in vivo. The BN derivative conjugated with a PEG(5) molecule showed the best pharmacokinetics in vivo, i.e., faster blood clearance and preferential renal excretion. The tumor uptake of the (99m)Tc-PEG(5)-Lys-BN conjugate was slightly higher compared to that of the non-PEGylated analogue (3.91%±0.44% vs. 2.80%±0.28% injected dose per gram 1 h postinjection, p.i.). Tumor retention was also increased, resulting in a threefold higher amount of radioactivity in the tumor at 24 h p.i. Furthermore, decreased hepatobiliary excretion and increased tumor-to-nontarget ratios (tumor-to-blood: 17.1 vs. 2.1; tumor-to-kidney: 1.1 vs. 0.4; tumor-to-liver: 5.8 vs. 1.0, 24 h p.i.) were observed and further confirmed via small-animal SPECT images 1 h p.i.
Conclusion: PEGylation proved to be an effective strategy to enhance the tumor-targeting potential of (99m)Tc-labeled BN-based radiopharmaceuticals and probably other radiolabeled peptides.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
- Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics.Okarvi SM, Jammaz IA.Okarvi SM, et al.Nucl Med Biol. 2012 Aug;39(6):795-804. doi: 10.1016/j.nucmedbio.2012.01.002. Epub 2012 Mar 3.Nucl Med Biol. 2012.PMID:22381782
- Spacer site modifications for the improvement of the in vitro and in vivo binding properties of (99m)Tc-N(3)S-X-bombesin[2-14] derivatives.Fragogeorgi EA, Zikos C, Gourni E, Bouziotis P, Paravatou-Petsotas M, Loudos G, Mitsokapas N, Xanthopoulos S, Mavri-Vavayanni M, Livaniou E, Varvarigou AD, Archimandritis SC.Fragogeorgi EA, et al.Bioconjug Chem. 2009 May 20;20(5):856-67. doi: 10.1021/bc800475k.Bioconjug Chem. 2009.PMID:19344122
- Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.Santos-Cuevas CL, Ferro-Flores G, Arteaga de Murphy C, Ramírez Fde M, Luna-Gutiérrez MA, Pedraza-López M, García-Becerra R, Ordaz-Rosado D.Santos-Cuevas CL, et al.Int J Pharm. 2009 Jun 22;375(1-2):75-83. doi: 10.1016/j.ijpharm.2009.04.018. Epub 2009 Apr 22.Int J Pharm. 2009.PMID:19393305
- 99mTc-Labeled, PEGylated (NαHis)Ac-β3hLys-βAla-βAla-Gln7-Trp8-Ala9-Val10-Gly11-His12-Cha13-Nle14-NH2.Shan L.Shan L.2012 Mar 12 [updated 2012 Apr 11]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013.2012 Mar 12 [updated 2012 Apr 11]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013.PMID:22514805Free Books & Documents.Review.
- 99mTc(v)O-Gly-Gly-Cys-Orn-Orn-Orn-Bombesin[2-14].Shan L.Shan L.2009 Aug 19 [updated 2009 Sep 23]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013.2009 Aug 19 [updated 2009 Sep 23]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013.PMID:20641903Free Books & Documents.Review.
Cited by
- Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.Baratto L, Jadvar H, Iagaru A.Baratto L, et al.Mol Imaging Biol. 2018 Aug;20(4):501-509. doi: 10.1007/s11307-017-1151-1.Mol Imaging Biol. 2018.PMID:29256046Free PMC article.Review.
- Radiolabelled peptides for oncological diagnosis.Laverman P, Sosabowski JK, Boerman OC, Oyen WJ.Laverman P, et al.Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S78-92. doi: 10.1007/s00259-011-2014-7.Eur J Nucl Med Mol Imaging. 2012.PMID:22388627Free PMC article.Review.
- Bombesin analogue-mediated delivery preferentially enhances the cytotoxicity of a mitochondria-disrupting peptide in tumor cells.Yang H, Cai H, Wan L, Liu S, Li S, Cheng J, Lu X.Yang H, et al.PLoS One. 2013;8(2):e57358. doi: 10.1371/journal.pone.0057358. Epub 2013 Feb 25.PLoS One. 2013.PMID:23451211Free PMC article.
- Bombesin-Targeted Delivery of β-Carboline-Based Ir(III) and Ru(II) Photosensitizers for a Selective Photodynamic Therapy of Prostate Cancer.Sanz-Villafruela J, Bermejo-Casadesús C, Riesco-Llach G, Iglesias M, Martínez-Alonso M, Planas M, Feliu L, Espino G, Massaguer A.Sanz-Villafruela J, et al.Inorg Chem. 2024 Oct 14;63(41):19140-19155. doi: 10.1021/acs.inorgchem.4c02583. Epub 2024 Oct 3.Inorg Chem. 2024.PMID:39361042Free PMC article.
- Radiolabeled peptides: valuable tools for the detection and treatment of cancer.Fani M, Maecke HR, Okarvi SM.Fani M, et al.Theranostics. 2012;2(5):481-501. doi: 10.7150/thno.4024. Epub 2012 May 16.Theranostics. 2012.PMID:22737187Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources